Introduction: Recent research from specialist endocrine centers has highlighted racial disparities in access to care for individuals with type 1 diabetes (T1D). The aim of this study was to use real-world data to determine outcomes, including the use of technology, and achieved HbA1c levels for individuals with T1D in a large integrated healthcare delivery system in Northern California.
Methods: Using outpatient and hospital encounters from Sutter Health, individuals were included if most of the diabetic ICD codes between January 2021 and October 2023 were for T1D, and they had an insulin order. EHR extraction included physician orders, self-reported treatment, and self-reported race/ethnicity. One-way ANOVA and chi-squared test of independence were applied.
Results: A total of 7325 patients with T1D were identified. Minority groups were younger (Table). HbA1C values were significantly higher in Black and Hispanic populations compared to Whites. Excluding multiracial patients, continuous blood glucose monitors (CGM) and glucagon-like peptide 1 based therapies were also ordered at higher rates among minority groups. The use of hybrid closed-loop (HCL) systems is not significantly different among groups.
Conclusion: Although use of CGM occurred more frequently in minority groups, HbA1C values were higher compared to the White population. The use of HCL systems remails low across all groups.
S. Robinson: None. D.C. Klonoff: Consultant; Afon Technology Ltd, Better Therapeutics, Inc, Glucotrack, LIfecare, Nevro Corp., Novo Nordisk, Samsung, Thirdwayv Inc. L. Dean: None. A. Scott: None. R. Lane: None. D. Kerr: Advisory Panel; Abbott Diagnostics. Consultant; Sanofi, Better Therapeutics, Inc. Stock/Shareholder; Glooko, Inc.
